Primary study · included by 2 reviews

Deescalated 225Ac-PSMA-617 Versus 177Lu/225Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients.

Rathke 2024 · Rathke Hendrik, Winter Erik, Bruchertseifer Frank, et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024

Included by

Therapeutic outcomes of ²²⁵Ac/¹⁷⁷Lu-PSMA combination therapy in advanced metastatic Castration-Resistant prostate cancer: A systematic review and Meta-Analysis.

Non-Cochrane · intervention · 2026 · cited as Rathke 2024 · Reference 28; Table 1; Figure 2A

Outcome this study informs	Pooled effect	Evidence	Certainty
PSA decline of 50% or more (PSA50 response) [225Ac]Ac-/[177Lu]Lu-PSMA combination (tandem) radioligand therapy vs None (single-arm studies)	Proportion (random-effects, REML) 0.47 [0.37, 0.56]	8 studies · 323 participants	GRADE not reported
PSA decline of 50% or more (PSA50 response) [225Ac]Ac-/[177Lu]Lu-PSMA combination (tandem) radioligand therapy vs None (single-arm studies)	Proportion (random-effects, REML) 0.44 [0.32, 0.56]	6 studies · 169 participants	GRADE not reported

Beyond [177Lu]Lu-PSMA: a meta-analysis of safety and efficacy of emerging PSMA radioligand therapy agents.

Non-Cochrane · intervention · 2026 · cited as Rathke 2024 · Reference list refs 21-53; Table 2; Supplementary Table 5

The review does not say which of its outcomes this study informs.

2 including reviews in total.